-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 22, 2021, Adagene announced that it had reached a clinical cooperation agreement with MSD
CTLA-4 and PD-1 are considered to be two important checkpoint proteins of the immune system.
ADG116 is the main drug candidate of the new epitope antibody pipeline "NEObody" of Tianyan Pharmaceutical, and ADG126 is the main drug candidate of the safe antibody technology pipeline "SAFEbody"
Compared with the commonly used CTLA-4 therapy, ADG116 has a stronger antibody-dependent cell-mediated cytotoxicity (ADCC), which can specifically and efficiently eliminate regulatory T cells in the tumor microenvironment
▲Product pipeline of Tianyan Pharmaceutical (picture source: official website of Tianyan Pharmaceutical)
Note: The original text has been deleted
Reference materials:
[1] Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab).